Navigation Links
Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
Date:6/22/2009

Advisory Committee to Review Denosumab Data

THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has asked the company to participate in a meeting of the Reproductive Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. The RHDAC will review data supporting the Biologics License Application (BLA) for denosumab, a RANK Ligand inhibitor for which Amgen is seeking approval for prevention and treatment of postmenopausal osteoporosis and prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate or breast cancer.

"In the U.S., one woman in two over the age of 50 will experience an osteoporotic fracture in her remaining lifetime. Although osteoporosis treatments are available, there remains a need for other options that deliver robust efficacy and support adherence to therapy," said Sean Harper, M.D., chief medical officer and head of Global Development at Amgen. "Likewise, there is currently no approved treatment for the men and women receiving hormone ablation therapy for prostate or breast cancer who are at increased risk for bone loss and consequently fracture. We look forward to discussing the data from our denosumab trials in these settings with the members of the Committee."

Amgen's BLA submission contains data from six Phase 3 trials involving more than 11,000 patients and approximately 13,000 patient years of exposure to denosumab. Two Phase 3 pivotal studies with fracture endpoints, in the osteoporosis and prostate cancer settings, demonstrated denosumab's ability to reduce the incidence of fractures, and all six studies showed denosumab's ability to increase bone mineral density at all skeletal sites measured. In the two pivotal studies with fracture endpoints, the inc
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Calif. (PRWEB) June 02, 2015 ... build-to-order, independent blade-based and rackmount computing and storage ... announced the launch of its high density scale-out, ... Cirrascale Slipstream™ RM1622D . The high density, ... E3-1200 v4 product family with Intel® Iris™ Pro ...
(Date:6/2/2015)... Pa. , June 2, 2015   ... be attending the BIO Exhibition 2015 in ... Exhibition, the world,s largest biotechnology gathering, allows influential ... high-level executives, where they can evaluate emerging technologies ... significant eClinical expertise in the design, implementation and ...
(Date:6/2/2015)... Pa. , June 2, 2015   BioClinica ... and technology provider, today announced that David Peters ... been named Executive Vice President and Chief Financial Officer ... 2015. Peters brings more than 25 years ... pharmaceutical services. "David has extensive and deep knowledge in ...
(Date:6/2/2015)... June 2, 2015   Sigma-Aldrich Corporation (NASDAQ: ... Technology company, announced today it has entered into ... launch genetically engineered human neural differentiated cells and ... of neurological diseases. These new products, in combination ... versatile tools for the study of central nervous ...
Breaking Biology Technology:Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2BioClinica Names David Peters New Chief Financial Officer 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3
... Ariz., June 23 MedPredict has published ... insight for pharma and,biotech companies hoping to ... The report, entitled "Thought Leader Insight & ... with a panel of,specialists in anesthesiology, psychiatry, ...
... dermatological portfolio, CORAL GABLES, Fla., June ... independent pharmaceutical company specializing in,dermatology, today announced ... to which Stiefel Laboratories will acquire Barrier ... through a two-step,transaction, a tender offer followed ...
... Product Suite by Adding Price Transparency, VERNON ... Concuity, a healthcare division of Trintech (Nasdaq: ... and revenue recovery technology ("Peer,Reviewed by HFMA") and ... (FHS Corp), a provider of a web-based solution,for ...
Cached Biology Technology:In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict 2Barrier Therapeutics to Merge Into Stiefel Laboratories 2Barrier Therapeutics to Merge Into Stiefel Laboratories 3Barrier Therapeutics to Merge Into Stiefel Laboratories 4Barrier Therapeutics to Merge Into Stiefel Laboratories 5Concuity Announces Partnership with Financial Healthcare Systems, LLC 2Concuity Announces Partnership with Financial Healthcare Systems, LLC 3Concuity Announces Partnership with Financial Healthcare Systems, LLC 4
(Date:5/22/2015)... May 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... will be ending its promotional pricing and making the Wocket ... Laurence Savin , Head of Marketing said, "We,ve extended ... until the end of May. To get your wocket at ... we open the store on June 1, you,ll receive a ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... molecular pathway could help physicians predict which lung cancer ... research from a multidisciplinary team at the University of ... suppressor, this fundamental molecule regulates cell proliferation in the ... either entirely inactive or altered in most human cancers. ...
... decade has witnessed an explosion of information regarding the ... development of obesity and the influence of peripheral, hormonal ... and metabolism. A symposium held recently in Washington, DC, ... work in talks by leaders in the field. ...
... mass extinction of life in Earths history 252 ... clam-like organisms called brachiopods dominated. After the calamity, when ... called a bivalve, took over. What can the ... surviving an extinction event" A lot, says UWM ...
Cached Biology News:UC health news: molecular pathway may predict chemotherapy effectiveness 2Obesity and the central nervous system -- the state of the art 2When bivalves ruled the world 2When bivalves ruled the world 3
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Biology Products: